Supplemental table 1. Characteristics of the DAA population by ethnicity

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Characteristic | Caucasian(n = 239) | Asian(n = 67) | African American(n = 25) | Hispanic(n = 154) | *p-*value |
| Medical Comorbidities* Coronary artery disease
* Chronic kidney disease
* Chronic obstructive pulmonary disease
* Diabetes Mellitus
 | 15%23.9%6.3%34.3% | 10.5%31.3%3%38.8% | 16%28%8%40% | 13.6%27.9%2.6%42.2% | 0.80.60.280.46 |
| Liver-related comorbidities* Cirrhosis
* Decompensated cirrhosis
* Hepatitis B coinfection
* Hepatocellular carcinoma
 | 81.2%71.6%3.4%12.7% | 85.1%82.1%10.5%20.5% | 64%44%8%24% | 96.5%90.9%3.9%40.4% | < 0.001< 0.0010.080.42 |
| HCV genotype * 1
* 2
* 3
* 4
* 6
 | 69.4%13.5%16.1%1%0% | 46.3%5.6%7.4%1.9%39% | 94.1%5.9%0%0%0% | 68.4%6.9%21.4%3.4%0% | < 0.001 |
| Antiviral regimen (DAA era only)* Ledipasvir/sofosbuvir
* Simeprevir/sofosbuvir
* Sofosbuvir/ribavirin
* Daclatasvir/sofosbuvir
* Pegylated interferon, ribavirin, and sofosbuvir
* Other regimen
 | 41.8%25.3%17.5%4.6%1.6%9.3% | 48.1%23.1%19.2%0%3.9%5.8% | 66.7%26.7%0%0%0%6.7% | 41.2%26.3%17.5%6%1.8%7% | 0.72 |
| Reasons for treatment delay (n = 59)* Insurance delays/denials
* Patient choice
* Financial stability
* Comorbidities/medications
* Unexplained
 | 13 (46.4%)3 (10.7%)2 (7.1%)2 (7.1%)8 (28.6%) | 3 (33.3%)1 (11.1%)02 (22.2%)3 (33.3%) | 1 (50%)001 (50%)0 | 13 (65%)2 (10%)03 (15%)2 (10%) | 0.61 |
| Reasons for non-treatment (n = 110)* Patient choice
* Issues with follow up
* Insurance issues or access
* Other reason
* Management of comorbidities
 | 1 (2.2%)8 (17.8%)5 (11.1%)15 (33.3%)16 (35.6%) | 04 (26.7%)03 (20%)8 (53.3%) | 03 (30%)1 (10%)2 (20%)4 (40%) | 012 (30%)2 (5%)8 (20%)18 (45%) | 0.77 |

Supplemental table 2. Multivariate and univariate analysis of predictors of treatment in the IFN-era

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Variables | Odds Ratio Univariate | 95% Confidence Interval | p-value | Odds Ratio Multivariate | 95% Confidence Interval | p-value |
| Age (per increase in year) | 0.97 | 0.96 – 0.98 | < 0.001 | 0.97 | 0.96 – 0.98 | < 0.001 |
| Male | 0.88 | 0.74 – 1.1 | 0.19 | - | - | - |
| Ethnicity* Caucasian
* Asian
* African American
* Hispanic
* Others
 | Referent1.10.840.620.81 | 0.82 – 1.40.57 – 1.20.48 – 0.810.54 – 1.2 | 0.60.370.020.32 | Referent1.30.810.610.83 | 0.93 – 1.70.53 – 1.30.46 – 0.820.5 – 1.4 | 0.130.34< 0.0010.47 |
| Decompensated cirrhosis | 0.57 | 0.47 – 0.69 | < 0.001 | 0.59 | 0.47 – 0.73 | < 0.001 |
| ≥ 2 vs. < medical comorbidities\* | 0.71 | 0.51 – 0.98 | 0.039 | 0.9 | 0.64 – 1.3 | 0.54 |
| History of psychiatric disorder† | 0.99 | 0.82 – 1.2 | 0.93 | - | - | - |

\*Medical comorbidities include coronary artery disease, chronic obstructive pulmonary disease, chronic kidney disease, and diabetes mellitus

†Psychiatric disorders include depression, bipolar disorder, and schizophrenia